Abstract Details

Title Investigating the relationship of Miller Fisher Syndrome and COVID-19 Vaccination: A Vaccine Adverse Event Reporting (VAERS) Study

Topic Infectious Disease

Presentation(s) P4 - Poster Session 4 (8:00 AM-9:00 AM)

Poster/Presentation
Number 4-001

Objective To investigate whether there is an relationship between Miller Fisher Syndrome (MFS) and COVID-19 vaccination

Background MFS was rarely reported after COVID-19 vaccination.

Design/Methods The reporting rate of MFS cases after COVID-19 vaccination was compared to the rate after all other vaccinations in 3 time periods: COVID-19 vaccination (December 2020 – July 2021); COVID-19 pandemic outside the vaccination time period (April 2020-November 2020) and the time outside of COVID-19 vaccination and the pandemic (January 2019-August 2019). Self-controlled case series analysis and case-centered analysis was used. Six weeks after vaccination was defined as the risk period of possible association.

Results 12 cases after COVID-19 vaccination and 1 case from all other vaccinations were reported during the vaccine period. The reporting rate of MFS after COVID-19 vaccination (0.62 per 10 million vaccinations) was significantly higher than the rate after other vaccinations (0.04 per 10 million vaccinations) p<0.05. Both reporting rates are within the incidence range expected in the general population. No cases of MFS were reported during the pandemic period and 2 cases of MFS were reported outside the pandemic period. Using self-controlled and case centered analyses, there was a significant difference in the reporting rate of MFS after COVID-19 vaccination between the risk period and control period (91.6% vs 0-8,3% p<0.00001). The reporting rate of MFS after each vaccine used in USA (Johnson & Johnson, Pfizer and Moderna) was within the expected incidence range and there was no significant difference between them.

Conclusions

There is no association between MFS and COVID-19 vaccination. Although the reporting rate MFS after COVID-19 was significantly higher during the risk period compared to control period, and compared to the rate of other vaccines, the number of reported cases was low and within the expected incidence range. Furthermore, cases of MFS related to COVID-19 infection or other triggering factors cannot be excluded.

Authors/Disclosures
Jorge L. Rodriguez Lee, MD (Yale School of Medicine) PRESENTER	Dr. Rodriguez Lee has nothing to disclose.
Mustafa Jaffry	Mr. Jaffry has nothing to disclose.
Kranthi K. Mandava	Mr. Mandava has nothing to disclose.
	No disclosure on file
	No disclosure on file
Kazim Jaffry	Mr. Jaffry has nothing to disclose.
	No disclosure on file
Nizar Souayah, MD, FAAN (NJMS)	Dr. Souayah has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Takeda. Dr. Souayah has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��